| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:ARN22089
CAS:2248691-29-2
Package:50mg/RMB 13800
|
| Company Name: |
Henan Yinuokai New Materials Co., Ltd.
|
| Tel: |
15670530983 |
| Email: |
3872928368@qq.com |
| Products Intro: |
Product Name:1,3-Benzenediamine, N1,N1-dimethyl-N3-[6-phenyl-2-(4-piperidinyl)-4-pyrimidinyl]-
CAS:2248691-29-2
Purity:95% Package:5mg;10mg;25mg
|
|
| | 1,3-Benzenediamine, N1,N1-dimethyl-N3-[6-phenyl-2-(4-piperidinyl)-4-pyrimidinyl]- Basic information |
| | 1,3-Benzenediamine, N1,N1-dimethyl-N3-[6-phenyl-2-(4-piperidinyl)-4-pyrimidinyl]- Chemical Properties |
| Boiling point | 576.6±50.0 °C(Predicted) | | density | 1.158±0.06 g/cm3(Predicted) | | pka | 9.51±0.10(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | 1,3-Benzenediamine, N1,N1-dimethyl-N3-[6-phenyl-2-(4-piperidinyl)-4-pyrimidinyl]- Usage And Synthesis |
| Uses | ARN22089 is a oral active novel class of trisubstituted pyrimidine, blocks the interaction of CDC42 GTPases with specific downstream effectors. ARN22089 blocks tumor growth in BRAF mutant mouse melanoma model[1]. | | References | [1] Brindani N, et al. Design, Synthesis, In Vitro and In Vivo Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer. J Med Chem. 2023;66(8):5981-6001. DOI:10.1021/acs.jmedchem.3c00276 |
| | 1,3-Benzenediamine, N1,N1-dimethyl-N3-[6-phenyl-2-(4-piperidinyl)-4-pyrimidinyl]- Preparation Products And Raw materials |
|